tbuckley/cabot-search huggingface dataset:
Issue Information
Authors: Daniel Solomon, Richard Bucala, New Haven, Mariana Kaplan, Peter Nigrovic, Boston Co, Karen Costenbader, David Felson, Richard Loeser, Chapel Hill, Paul Sufka, St Paul, Amr Sawalha, Susan Boackle, Aileen Davis, Deborah Feldman, Donnamarie Krause, Las Vegas, Wilson Kuswanto, Michelle Ormseth, Nashville Scofield, Oklahoma City, Kimberly Murphy, Lesley Allen, Virginia Ilani, S Lorber, Stefanie Mckain, Georgia Rasa, G Hamilton, Brian Robinson, Christopher Reynolds, Georgia Jenson, Marta Alarcón-Riquelme, Heather Allore, Neal Basu, Edward Behrens, Bryce Binstadt, Nunzio Bottini, San Diego, John Carrino, New York, Andrew Cope, Adam Croft, Nicola Dalbeth, Brian Feldman, Richard Furie, Great Neck, J Kahlenberg, Ann Arbor, Benjamin Leder, Yvonne Lee, Katherine Liao, Bing Lu, Stephen Messier, Winston-Salem Rachel, E Miller, Janet Pope, Lisa Rider, Christopher Ritchlin, Rochester Robinson, Carla Scanzello, Georg Schett, Sakae Tanaka, Maria Trojanowska, Betty Tsao, Fredrick Wigley, Edith Williams, Ayaz Aghayev, Joshua Baker, Bonnie Bermas, Jamie Collins, Kristen Demoruelle, Denver Denton, Anisha Dua, John Fitzgerald, Angeles Henderson, Monique Hinchcliff, Hui-Chen Hsu, Mohit Kapoor, Seoyoung Kim, Vasileios Kyttaris, Carl Langefeld, Winston-Salem Dennis Mcgonagle, Julie Paik, Julie Zikherman, Francisco American, Douglas White, La Crosse, Deborah Desir, Carol Langford, Steven Echard, Jeff Curtis, Sindhu Johnson, Donald Anthony, Reuben Arasaratnam, Lindsey Baden, Anne Bass, Cassandra Calabrese, Ellen Gravallese, Rafael Harpaz, Andrew Kroger, Peter Stoustrup, Cory Resnick, Shelly Abramowicz, Thomas Pedersen, Ambra Michelotti, Annelise Küseler, Bernd Koos, Carlalberta Verna, Ellen Nordal, Eric Granquist, Josefi Ne, Mareile Halbig, Kasper Kristensen, Leonard Kaban, Linda Arvidsson, Lynn Spiegel, Matthew Stoll, Melissa Lerman, Mia Glerup, Patrizia Defabianis, Paula Frid, Per Alstergren, Randy Cron, Sarah Ringold, Sven Nørholt, Christopher Dunn, Cassandra Sturdy, Cassandra Velasco, Leoni Schlupp, Emmaline Prinz, Magali Berland, Victoria Meslier, Berreira Ibraim, Emmanuelle Le Chatelier, Nicolas Pons, Nicolas Maziers, Florence Thirion, Franck Gauthier, Florian Oñate, Jean-Pierre Furet, Ariane Leboime, Roula Said-Nahal, Florence Levenez
Journal: Arthritis & Rheumatology (2022)
Table of Contents
Authors: Adithya Balasubramanian, Thomas John, Amy Colori, Crispin Hiley, Jeffrey Ahn, Misako Nagasaka, Qian Wang, Zeynep Gümüs ¸, Cristina Colarossi, Lorenzo Memeo, Xintong Wang, Chung Kong, Paolo Boffetta, Ching-Yao Yang, Yen-Ting Lin, Li-Ju Lin, Ya-Hsuan Chang, Hsuan-Yu Chen, Yi-Pin Wang, Jin-Yuan Shih, Chong-Jen Yu, Pan-Chyr Yang
Journal: Journal of Thoracic Oncology (2022)
Clinical practice guidelines: management of severe bronchiolitis in infants under 12 months old admitted to a pediatric critical care unit
Authors: Christophe Milési, Florent Baudin, Philippe Durand, Guillaume Emeriaud, Sandrine Essouri, Robin Pouyau, Julien Baleine, Sophie Beldjilali, Alice Bordessoule, Sophie Breinig, Pierre Demaret, Philippe Desprez, Bénédicte Gaillard-Leroux, Julie Guichoux, Anne-Sophie Guilbert, Camille Guillot, Sandrine Jean, Michael Levy, Odile Noizet-Yverneau, Jérôme Rambaud, Morgan Recher, Stéphanie Reynaud, Fréderic Valla, Karim Radoui, Marie-Agnes Faure, Guillaume Ferraro, Guillaume Mortamet
Journal: Intensive Care Medicine (2023)
The Composite Immune Risk Score predicts overall survival after allogeneic hematopoietic stem cell transplantation: A retrospective analysis of 1838 cases
Authors: Yigeng Cao, Xiaowen Gong, Yahui Feng, Mingyang Wang, Yu Hu, Huilan Liu, Xueou Liu, Saibing Qi, Yanping Ji, Fang Liu, Huaiping Zhu, Wenwen Guo, Qiujin Shen, Rongli Zhang, Ningning Zhao, Weihua Zhai, Xiaoqiang Song, Xin Chen, Liangquan Geng, Xia Chen, Xuetong Zheng, Qiaoling Ma, Baolin Tang, Jialin Wei, Yong Huang, Yuanyuan Ren, Kaidi Song, Donglin Yang, Aiming Pang, Wen Yao, Yi He, Yue Shang, Xiang Wan, Wei Zhang, Song Zhang, Guangyu Sun, Sizhou Feng, Xiaofan Zhu, Mingzhe Han, Zhen Song, Ye Guo, Zimin Sun, Erlie Jiang, Junren Chen
Journal: American Journal of Hematology (2023)

There has been little consensus on how to quantitatively assess immune reconstitution after hematopoietic stem cell transplantation (HSCT) as part of the standard of care. We retrospectively analyzed 11 150 post-transplant immune profiles of 1945 patients who underwent HSCT between 2012 and 2020. 1838 (94.5%) of the cases were allogeneic HSCT. Using the training set of patients (n = 729), we identified a composite immune signature (integrating neutrophil, total lymphocyte, natural killer, total T, CD4
Wnt signaling regulates MFSD2A-dependent drug delivery through endothelial transcytosis in glioma
Authors: Yuan Xie, Liqun He, Yanyu Zhang, Hua Huang, Fan Yang, Min Chao, Haiyan Cao, Jianhao Wang, Yaling Li, Lingxue Zhang, Lele Xin, Bing Xiao, Xinxin Shi, Xue Zhang, Jiefu Tang, Lene Uhrbom, Anna Dimberg, Liang Wang, Lei Zhang
Journal: Neuro-Oncology (2023)

Abstract Background Systemic delivery of anti-tumor therapeutic agents to brain tumors is thwarted by the blood-brain barrier (BBB), an organotypic specialization of brain endothelial cells (ECs). A failure of pharmacological compounds to cross BBB is one culprit for the dismal prognosis of glioblastoma (GBM) patients. Identification of novel vascular targets to overcome the challenges posed by the BBB in tumors for GBM treatment is urgently needed. Methods Temozolomide (TMZ) delivery was investigated in CT2A and PDGFB-driven RCAS/tv-a orthotopic glioma models. Transcriptome analysis was performed on ECs from murine gliomas. Mfsd2a deficient, Cav1 deficient, and Mfsd2a EC-specific inducible mice were developed to study the underlying molecular mechanisms. Results We demonstrated that inhibiting Wnt signaling by LGK974 could increase TMZ delivery and sensitize glioma to chemotherapy in both murine glioma models. Transcriptome analysis of ECs from murine gliomas revealed that Wnt signaling inhibition enhanced vascular transcytosis as indicated by the upregulation of PLVAP and downregulation of MFSD2A. Mfsd2a deficiency in mice enhances TMZ delivery in tumors, whereas constitutive expression of Mfsd2a in ECs suppresses the enhanced TMZ delivery induced by Wnt pathway inhibition in murine glioma. In addition, Wnt signaling inhibition enhanced caveolin-1 (Cav1)-positive caveolae-mediated transcytosis in tumor ECs. Moreover, Wnt signaling inhibitor or Mfsd2a deficiency fails to enhance TMZ penetration in tumors from Cav1-deficient mice. Conclusions These results demonstrated that Wnt signaling regulates MFSD2A-dependent TMZ delivery through a caveolae-mediated EC transcytosis pathway. Our findings identify Wnt signaling as a promising therapeutic target to improve drug delivery for GBM treatment.
Idarubicin plus <scp>BuCy</scp> versus <scp>BuCy</scp> conditioning regimens for intermediate‐risk acute myeloid leukemia in first complete remission undergoing <scp>auto‐HSCT</scp>: An open‐label, multicenter, randomized phase 3 trial
Authors: Hui Liu, Fen Huang, Yu Zhang, Meiqing Wu, Na Xu, Zhiping Fan, Zhiqiang Sun, Xudong Li, Dongjun Lin, Yiying Xiong, Xiaodan Liu, Ren Lin, Pengcheng Shi, Jun Xu, Zhixiang Wang, Xiaofang Li, Jing Sun, Qifa Liu, Li Xuan
Journal: American Journal of Hematology (2023)

Abstract We report a randomized prospective phase 3 study, designed to evaluate the efficacy and tolerability of idarubicin plus busulfan and cyclophosphamide (IDA‐BuCy) versus BuCy in autologous hematopoietic stem‐cell transplantation (auto‐HSCT) for intermediate‐risk acute myeloid leukemia (IR‐AML) patients in first complete remission (CR1). One hundred and fifty‐four patients were enrolled and randomized to receive IDA‐BuCy (IDA 15 mg/m2/day on days −12 to −10, Bu 3.2 mg/kg/day on days −7 to −4, and Cy 60 mg/kg/day on days −3 to −2) or BuCy. The 2‐year incidence of relapse was 15.6% and 19.5% in IDA‐BuCy and BuCy groups ( p = 0.482), respectively. There was no significant overall survival (OS) and disease‐free survival (DFS) benefit for IR‐AML patients receiving IDA‐BuCy (2‐year OS 81.8% in IDA‐BuCy vs. 83.1% in BuCy, p = 0.798; 2‐year DFS 76.6% in IDA‐BuCy vs. 79.2% in BuCy, p = 0.693). Grade 3 or worse regimen‐related toxicity (RRT) was reported for 22 (28.9%) of 76 and 9 (12.0%) of 75 patients in two groups ( p = 0.015), respectively. AEs within 100 days with an outcome of death were reported for 4 (5.3%) and 0 patients in two groups. In conclusion, IDA‐BuCy has higher RRT and similar anti‐leukemic activity compared with BuCy in IR‐AML patients in CR1 undergoing auto‐HSCT. Thus, caution should be taken when choosing IDA‐BuCy for IR‐AML patients in CR1 with auto‐HSCT. This trial is registered with ClinicalTrials.gov , NCT02671708, and is complete.
Survival trends in young patients with Waldenström macroglobulinemia: Over five decades of experience
Authors: Karan L. Chohan, Jonas Paludo, Nishanth Vallumsetla, Dirk Larson, Rebecca L. King, Rong He, Wilson Gonsalves, David Inwards, Thomas E. Witzig, Abhisek Swaika, Tania Jain, Nelson Leung, Sikander Ailawadhi, Craig B. Reeder, Martha Q. Lacy, S. Vincent Rajkumar, Shaji Kumar, Robert A. Kyle, Morie A. Gertz, Stephen M. Ansell, Prashant Kapoor
Journal: American Journal of Hematology (2023)

Waldenström macroglobulinemia (WM) is a rare, indolent lymphoma, that predominately affects the elderly. We report the outcomes of young WM patients, evaluated over five decades, compared to their older counterparts, matched for the time of diagnosis. Between January 1, 1960 and October 31, 2013, 140 (11.8%) WM patients were ≤50 years of age at diagnosis in our database, and their estimated 10-year overall survival (OS) was 74%, with death attributable to WM in a higher proportion of patients compared to their older (≥65 years) counterparts (91% vs. 58%, p = .0001). Young patients were grouped into three cohorts based on the timing of the initiation of therapy: Group 1 (1960-1977, n = 12), Group 2 (1978-1995, n = 48), and Group 3 (1996-2013, n = 74). Among young patients, there was no disease-specific survival (DSS) difference across the three periods, [median DSS at 13 years (95% CI 5-23), 16 years (95% CI 14-22), and 15 years (95% CI 10-NR; p = .41), respectively]. However, DSS for the older cohort incrementally improved (Group 1, median 5.2 years, Group 2: 9.6 years, Group 3: 12 years; p = .05) over these periods. The estimated average years-of-life lost for the young cohort was 11.2 years from diagnosis, based on the expected survival for a normal age- and sex-matched population. Despite a protracted disease course, nearly all young patients succumb to their disease. In contrast to the improved survival of the elderly patient population, the evolving treatment strategies in WM have not impacted the outcome of young patients; however, the impact of Bruton tyrosine kinase inhibitors on this unique patient population remains to be determined.
Overall and complication‐free survival in a large cohort of patients with <i>β</i> ‐thalassemia major followed over 50 years
Authors: Gian Luca Forni, Barbara Gianesin, Khaled M. Musallam, Filomena Longo, Rosamaria Rosso, Roberto Lisi, Maria Rita Gamberini, Valeria Maria Pinto, Giovanna Graziadei, Angelantonio Vitucci, Federico Bonetti, Pellegrino Musto, Antonio Piga, Maria Domenica Cappellini, Caterina Borgna‐Pignatti
Journal: American Journal of Hematology (2023)

Abstract We report data on survival and complications for a longitudinal cohort of 709 transfusion‐dependent β ‐thalassemia major patients (51.1% males) born between 1970 and 1997 and followed through 2020 at seven major centers in Italy. Overall survival probability at 30 years was 83.6% (95%CI: 78.5–89.1) in the oldest birth cohort (1970–1974) compared with 93.3% (95%CI: 88.6–98.3) in the youngest birth cohort (1985–1997) ( p = 0.073). Females showed better survival than males ( p = 0.022). There were a total of 93 deaths at a median age of 23.2 years with the most frequent disease‐related causes being heart disease ( n = 53), bone marrow transplant (BMT) complication ( n = 10), infection ( n = 8), liver disease ( n = 4), cancer ( n = 3), thromboembolism ( n = 2) and severe anemia ( n = 1). There was a steady decline in the number of deaths due to heart disease from the year 2000 onwards and no death from BMT was observed after the year 2010. A progressive decrease in the median age of BMT was observed in younger birth cohorts ( p &lt; 0.001). A total of 480 (67.7%) patients developed ≥1 complication. Patients in younger birth cohorts demonstrated better complication‐free survival ( p &lt; 0.001) which was comparable between sexes ( p = 0.230). Independent risk factors for death in multivariate analysis included heart disease (HR: 4.63, 95%CI: 1.78–12.1, p = 0.002), serum ferritin &gt;1000 ng/mL (HR: 15.5, 95%CI: 3.52–68.2, p &lt; 0.001), male sex (HR: 2.75, 95%CI: 0.89–8.45, p = 0.078), and splenectomy (HR: 6.97, 95%CI: 0.90–54.0, p &lt; 0.063). Survival in patients with β ‐thalassemia major continues to improve with adequate access to care, best practice sharing, continued research, and collaboration between centers.
Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approach
Authors: Matthew J. Pianko, Timothy Tiutan, Andriy Derkach, Jessica Flynn, Steven P. Salvatore, Insara Jaffer‐Sathick, Adriana C. Rossi, Oscar Lahoud, Malin Hultcrantz, Urvi A. Shah, Kylee Maclachlan, David J. Chung, Gunjan L. Shah, Heather J. Landau, Neha Korde, Sham Mailankody, Alexander M. Lesokhin, Carlyn Tan, Michael Scordo, Edgar A. Jaimes, Sergio A. Giralt, Saad Usmani, Hani Hassoun
Journal: American Journal of Hematology (2023)

Abstract Monoclonal immunoglobulin deposition disease (MIDD), often associated with plasma cell dyscrasias, predominantly affects the kidneys. In this disease, hematologic response (HR) to treatment can be reliably assessed by International Myeloma Working Group (IMWG) consensus criteria, while uniform criteria for assessing renal response are lacking. We report a retrospective analysis of renal outcomes among 34 patients with MIDD. With most patients treated with bortezomib and autologous stem cell transplantation, 26 of 28 (94%) achieved very good partial HR or better. We demonstrate that both IMWG (based on estimated glomerular filtration rate, eGFR) and amyloid (based on proteinuria) criteria are needed to capture renal response: among 28 evaluable patients, 6 (21%) had isolated proteinuria, while 13 (46%) had isolated decreased eGFR. Using both criteria, which were concordant in patients with both decreased eGFR and proteinuria, 22 of 28 patients (79%) achieved a renal response, including 2 of 7 discontinuing dialyses. All 6 patients (100%) with isolated proteinuria and 7 of 13 (54%) with isolated decreased eGFR achieved renal response, suggesting that isolated proteinuria is an early manifestation of MIDD associated with reversible renal damage. Baseline eGFR predicted renal response ( p = .02 by quartile) and survival ( p = .02), while HR (CR vs. non‐CR) did not, probably because of high HR rate. With a median follow‐up of 110 months, the median overall survival was 136 months (95% CI: 79–NR) and median renal survival had not been reached. Prospective studies using uniform renal response criteria are needed to optimize the management of MIDD.
High‐Performance Delivery of a CRISPR Interference System via Lipid‐Polymer Hybrid Nanoparticles Combined with Ultrasound‐Mediated Microbubble Destruction for Tumor‐Specific Gene Repression
Authors: Yan Li, Pengying Wu, Mingting Zhu, Meiling Liang, Lei Zhang, Yujin Zong, Mingxi Wan
Journal: Advanced Healthcare Materials (2023)

Abstract The dCas9‐based CRISPR interference (CRISPRi) system efficiently silences genes without causing detectable off‐target activity, thus showing great potential for the treatment of cancer at the transcriptional level. However, due to the large size of the commonly used CRISPRi system, effective delivery of the system has been a challenge that hinders its application in the clinic. Herein, a combination of pH‐responsive lipid‐polymer hybrid nanoparticles (PLPNs) and ultrasound‐mediated microbubble destruction (UMMD) is used for the delivery of the CRISPRi system. The core–shell structure of PLPNs can effectively be loaded with the CRISPRi plasmid, and increases the time spent in the circulating in vivo, and “actively target” cancer cells. Moreover, the combination of PLPNs with UMMD achieves a higher cellular uptake of the CRISPRi plasmid in vitro and retention in vivo. Furthermore, when PLPNs loaded with a CRISPRi plasmid that targets microRNA‐10b (miR‐10b) are used in combination with UMMD, it results in the effective repression of miR‐10b in breast cancer, simultaneous disturbance of multiple cell migration and invasion‐related signaling pathways, and a significant inhibition of lung metastasis. Thus, the established system presents a versatile, highly efficient, and safe strategy for delivery of the CRISPRi system both in vitro and in vivo.
Complications and treatment errors in nonsurgical periodontal therapy
Authors: Filippo Graziani, Manuel Tinto, Chiara Orsolini, Rossana Izzetti, Cristiano Tomasi
Journal: Periodontology 2000 (2023)

Abstract Nonsurgical periodontal therapy can be subject to iatrogenesis, which includes all the complications directly or indirectly related to a treatment. These complications include both operator‐dependent harms and errors and the consequences and adverse effects of the therapeutic procedures. The complications arising following nonsurgical periodontal treatment can be categorized as intraoperative and postoperative and can affect both soft and hard tissues at an intra‐oral and extraoral level. Soft‐tissues damage or damage to teeth and restorations can occur while performing the procedure. In the majority of cases, the risk of bleeding associated with nonsurgical therapy is reported to be low and easily controlled by means of local hemostatic measures, even in medicated subjects. Cervicofacial subcutaneous emphysema is not a frequent extraoral intraoperative complication, occurring during the use of air polishing. Moreover, side effects such as pain, fever, and dentine hypersensitivity are frequently reported as a consequence of nonsurgical periodontal therapy and can have a major impact on a patient's perception of the treatment provided. The level of intraoperative pain could be influenced by the types of instruments employed, the characteristics of tips, and the individual level of tolerance of the patient. Unexpected damage to teeth or restorations can also occur as a consequence of procedural errors.
Clinico‐genetic and prognostic analyses of 716 patients with primary <scp>myelodysplastic syndrome</scp> and <scp>myelodysplastic syndrome/acute myeloid leukemia</scp> based on the 2022 International Consensus Classification
Authors: Wan‐Hsuan Lee, Chien‐Chin Lin, Cheng‐Hong Tsai, Feng‐Ming Tien, Min‐Yen Lo, Sao‐Chih Ni, Ming Yao, Mei‐Hsuan Tseng, Yuan‐Yeh Kuo, Ming‐Chih Liu, Jih‐Luh Tang, Hsun‐I Sun, Yi‐Kuang Chuang, Wen‐Chien Chou, Hsin‐An Hou, Hwei‐Fang Tien
Journal: American Journal of Hematology (2023)

Abstract The 2022 International Consensus Classification (ICC) recategorized myeloid neoplasms based on recent advances in the understanding of the biology of hematologic malignancies, in which myelodysplastic syndrome (MDS) with blasts of 10%–19% is classified as MDS/acute myeloid leukemia (AML), MDS with mutated SF3B1 , irrespective of the number of ring sideroblasts, as MDS‐ SF3B1 , and those with multi‐hit TP53 mutations as MDS with mutated TP53 . In the analysis of 716 patients with MDS diagnosed according to the 2016 WHO classification, we found that 75.3% of patients remained in the MDS group based on the ICC, while 24.7% of patients were reclassified to the MDS/AML group after the exclusion of 15 patients who were classified to the AML group. Patients with MDS/AML showed a distinct mutational landscape and had poorer outcomes, compared to those with MDS. In the MDS group, patients with MDS‐ SF3B1 had higher frequencies of DNMT3A and TET2 mutations than those with MDS, not otherwise specified, with single lineage dysplasia or multilineage dysplasia. Patients with mutated TP53 were associated with dismal outcomes, irrespective of the blast percentage. In conclusion, this study showed that the ICC facilitates efficient segregation and risk‐stratification of MDS which can help guide the treatment choice of patients with the disease.
A signature of differential gene expression in bronchoalveolar lavage fluid predicts mortality in influenza-associated pulmonary aspergillosis
Authors: Simon Feys, Jannes Heylen, Agostinho Carvalho, Johan Van Weyenbergh, Joost Wauters, Samuel M. Gonçalves, Cristina Cunha, Yves Debaveye, Greet Hermans, Stephanie Humblet-Baron, Cato Jacobs, Diether Lambrechts, Peter Mombaerts, Katrien Lagrou, Philippe Meersseman, Soraya Maria Menezes, Marijke Peetermans, Joana Rocha-Pereira, Laura Seldeslachts, Marick Rodrigues Starick, Karin Thevissen, Christophe Vandenbriele, Lore Vanderbeke, Greetje Vande Velde, Frank L. Van De Veerdonk, Alexander Wilmer
Journal: Intensive Care Medicine (2023)
Overcoming the Stromal Barrier of the Cornea with a Peptide Conjugate Nano‐Assembly to Combat Fungal Keratitis
Authors: Xiaoyan Ju, Liping Wu, Ning Gao, Ye Tian, Guojun Lu, Yichen Gao, Shaozhen Zhao, Zhongwei Niu, Ruibo Yang
Journal: Advanced Healthcare Materials (2023)

Abstract Fungal hyphae deeply invade the cornea in fungal keratitis. The corneal stroma hinders the infiltration of antifungal drugs and reduces their bioavailability. Here, this work reports a peptide conjugate nano‐assembly that permeates the stroma and kills the pathogen without irritating the ocular cornea. The hydrophilic surface of the nano‐assembly ensures deep permeation into the stroma. When encountering a fungal hyphal cell, the nano‐assembly disassembles and exposes the α ‐helical peptide to destroy the fungal membrane, thus inactivating the pathogen. In a rabbit model of fungal keratitis, the nano‐assembly exhibits a better therapeutic effect than commercially available natamycin ophthalmic suspension. Peptide conjugates with a nano‐assembled structure and assembly–disassembly behavior could serve as the foundation of a new therapy for fungal keratitis.
An artificial intelligence algorithm‐based smartphone application for daily cough monitoring
Authors: Ji‐Su Shim, Min‐Hye Kim, Sang Min Lee, Sae‐Hoon Kim, Jae‐Woo Kwon, Catherine Song, Kyung‐Min Ahn, Sung‐Yoon Kang, Han‐Ki Park, Heung‐Woo Park, Byung‐Keun Kim, Min‐Suk Yang
Journal: Allergy (2023)

Data S1 Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.